Merck KGaA Boosts Biotech Portfolio with JSR Acquisition

In a strategic move to enhance its biopharmaceutical capabilities, Germany’s Merck KGaA has finalised the acquisition of JSR Life Sciences’ chromatography business. This deal includes valuable Protein A chromatography technology and a robust team based in Belgium, significantly enriching Merck’s offerings in monoclonal antibody purification and downstream processing.

Merck KGaA, a leading player in the life sciences sector, has reinforced its stature by acquiring JSR Life Sciences’ advanced chromatography assets. This acquisition is timely, coinciding with growing demand for efficient biologics production. Integrating Protein A capabilities, renowned for their role in purifying antibodies and therapeutic proteins, positions Merck to better support biopharmaceutical manufacturers’ needs globally. These proteins are vital for treating autoimmune disorders, cancers, and infectious diseases. With over 62,000 employees and generating sales of €21.1 billion in 2025, Merck continues to demonstrate its commitment to enhancing biomanufacturing solutions. The addition of JSR’s operations, particularly the Amsphere Protein A resins, plays into Merck’s strategy to offer scalable purification solutions that bolster process consistency and reliable manufacturing. This aligns with an industry shift towards faster scaling of biologics.

Merck’s acquisition of JSR’s chromatography business is a significant step toward advancing global biopharmaceutical manufacturing capabilities. By expanding its process solutions portfolio, Merck is poised to play a crucial role in accelerating access to essential therapies, highlighting its foresight in biotech innovation and market leadership.